The European Medicines Agency recently finalized a reflection paper on the use of artificial intelligence (AI) during the lifecycle of medicinal products to help manufacturers use AI in a safe and effective way.
EMA’s AI Principles Intended To Be ‘Flexible & Long Lasting’
There is “a lot of flexibility” in the European Medicines Agency’s reflection paper on the use of artificial intelligence during drug development, which is principles-driven rather than setting rigid recommendations, says the agency’s Florian Lasch.
